No Patient or Illness to be Treated? The Hazards of Investigations Carried Out nder Article 102 TFEU for Price-Related Conduct (The Netherlands, Case 7069, AstraZeneca)

OnderzoeksoutputAcademicpeer review


This article discusses the decision of the netherlands competition authority in the AstraZeneca case and puts this in a broader perspective of regulation in the pharmaceutical market, price regulation and responses to market failures.
Originele taal-2English
Pagina's (van-tot)664-668
Aantal pagina's5
TijdschriftJournal of European Competition Law & Practice
Nummer van het tijdschrift9
Vroegere onlinedatum25-aug-2015
StatusPublished - 2015

Citeer dit